The IBTA’s monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.
You can also read the IBTA e-News October 2021 edition in full online here.
Some of the highlights from this month’s round-up:
- The 2021 International Brain Tumour Awareness Week took place on Saturday, 30th October 2021 to Saturday 6th November 2021)
- “Brilliance!” – the IBTA’s virtual exhibition of creative works from the global brain tumour community – went live on 4th November, with the publication of virtual art exhibition catalogue. Read more.
- The IBTA is proud to announce the launch of its new, monthly podcast series. “A Brain Tumour and Me – a journey of inspiration, personal stories and hope” Read more.
- Results published in Frontiers in Oncology from the Phase 3 EF14 clinical trial assessing the efficacy and safety of TTFields combined with maintenance temozolomide show significantly improved progression free survival (PFS) and overall survival (OS) in elderly patients with newly diagnosed glioblastoma.
- A study published in Nature Genetics has described how brain tumours adapt to biological stresses put upon them and become more aggressive when glioblastoma cells are exposed to low oxygen states and irradiation.
- A paper in Nature Communications authored by a team of scientists at Queen Mary University of London (UK) provides new insights into how glioblastoma tumours develop, potentially identifying new targets for individualised treatments.
- A clinical trial run by the National Cancer Institute (NCI), National Institutes of Health (NIH) in the United States is testing a new immunotherapy treatment to improve survival in patients with glioblastoma or gliosarcoma. A clinical trial run by the National Cancer Institute (NCI), National Institutes of Health (NIH) in the United States is testing a new immunotherapy treatment to improve survival in patients with glioblastoma or gliosarcoma.
- A new study in the European Journal of Pharmaceutics and Biopharmaceutics reports a novel method of delivering temozolomide across the blood brain barrier to target glioblastoma and brain cancer stem cells.
- Published in JAMA Ocology are findings from a randomised clinical trial of medulloblastoma patients aged 3 to 21 years of age defined as ‘high risk’, who were treated with a standard protocol of chemoradiation including weekly vincristine chemotherapy with or without daily carboplatin, followed by six cycles of maintenance chemotherapy with or without 12 cycles of a drug called isotretinoin.
- A study published in Science Translational Medicine has investigated whether the anti-diabetic drug metformin could improve survival for paediatric patients with ependymoma brain tumours by inhibiting a protein that is overexpressed in a subset of patients with the disease.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.
